`
`BLA Number
`125031
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`
`Applicant Name
`Amgen, Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`
`Proprietary Name
`Neulasta
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`
`Proper Name
`pegfilgrastim
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`
`Patent Number
`9,856,287
`6,805,686
`8,231,876
`8,420,081
`8,663,945
`8,708,968
`8,715,664
`8,808,700
`8,883,156
`8,889,136
`8,895,009
`8,906,372
`8,906,373
`8,906,646
`8,911,737
`8,911,964
`8,916,153
`8,926,975
`8,961,973
`8,961,974
`8,974,790
`8,986,693
`8,992,926
`8,999,337
`9,061,005
`9,062,106
`9,067,992
`9,085,618
`9,085,619
`9,085,620
`9,090,688
`9,090,689
`9,090,867
`9,096,666
`9,102,723
`9,150,645
`9,181,337
`9,181,572
`9,187,559
`
`Patent Expiration Date
`6/21/30
`2023-05-06
`2027-04-04
`2030-01-13
`2027-09-13
`2032-01-24
`2027-07-24
`2026-05-16
`2027-04-04
`2027-10-09
`2027-04-04
`2027-04-04
`2023-07-18
`2027-09-13
`2022-06-05
`2027-09-13
`2027-04-04
`2027-06-08
`2025-04-11
`2025-04-11
`2022-06-05
`2025-04-11
`2022-06-05
`2031-02-06
`2025-04-11
`2032-04-26
`2023-07-18
`2033-03-14
`2028-11-28
`2023-07-18
`2032-04-26
`2023-07-18
`2027-09-13
`2027-04-04
`2027-04-04
`2033-05-13
`2033-03-14
`2033-03-14
`2025-04-11
`
`https://purplebooksearch.fda.gov/patent-list
`
`Mylan Exhibit 1166
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`
`
`BLA Number
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125057
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`
`Applicant Name
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`AbbVie Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`
`Proprietary Name
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Humira
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`
`Proper Name
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`adalimumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`
`Patent Number
`9,234,032
`9,266,949
`9,273,132
`9,284,370
`9,284,371
`9,290,568
`9,315,574
`9,328,165
`9,334,319
`9,339,610
`9,346,879
`9,359,434
`9,499,614
`9,499,616
`9,505,834
`9,512,216
`9,522,953
`9,546,212
`9,550,826
`9,624,295
`9,669,093
`9,683,033
`9,708,400
`9,913,902
`9,957,318
`11,083,792
`11,167,030
`11,191,834
`10,906,986
`7,485,704
`8,460,895
`8,512,983
`8,574,869
`9,441,035
`9,487,809
`9,714,293
`9,795,672
`10,011,856
`10,017,732
`10,208,355
`10,274,466
`
`Patent Expiration Date
`2027-09-13
`2033-05-13
`2027-04-04
`2028-06-10
`2027-09-13
`2033-03-14
`2033-04-21
`2027-04-04
`2033-03-14
`2032-01-24
`2033-03-14
`2033-03-14
`2034-03-14
`2033-03-14
`2032-04-26
`2025-04-11
`2032-04-26
`2022-06-05
`2034-11-14
`3031-03-31
`2028-06-10
`2032-04-26
`2033-03-14
`2027-04-04
`2032-04-26
`4/4/27
`11/28/28
`11/28/28
`2028-07-08T00:00:00.000Z
`2025-03-08T00:00:00.000Z
`2029-03-11T00:00:00.000Z
`2031-01-04T00:00:00.000Z
`2028-07-08T00:00:00.000Z
`2034-04-23T00:00:00.000Z
`2032-01-14T00:00:00.000Z
`2030-08-06T00:00:00.000Z
`2024-05-28T00:00:00.000Z
`2031-05-26T00:00:00.000Z
`2034-03-14T00:00:00.000Z
`2035-07-14T00:00:00.000Z
`2035-07-11T00:00:00.000Z
`
`https://purplebooksearch.fda.gov/patent-list
`
`Mylan Exhibit 1166
`Mylan v. Regeneron, IPR2021-00881
`Page 2
`
`
`
`BLA Number
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`125085
`125156
`125156
`125156
`125156
`125156
`125156
`125156
`125156
`125156
`125156
`125156
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`
`Applicant Name
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Genentech, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`
`Proprietary Name
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Avastin
`Lucentis
`Lucentis
`Lucentis
`Lucentis
`Lucentis
`Lucentis
`Lucentis
`Lucentis
`Lucentis
`Lucentis
`Lucentis
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`
`Proper Name
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`bevacizumab
`ranibizumab
`ranibizumab
`ranibizumab
`ranibizumab
`ranibizumab
`ranibizumab
`ranibizumab
`ranibizumab
`ranibizumab
`ranibizumab
`ranibizumab
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`
`Patent Number
`10,336,983
`10,513,697
`10,662,237
`10,676,710
`10,704,071
`10,829,732
`10,906,934
`10,982,003
`11,078,294
`6,716,602
`6,828,121
`6,921,659
`8,574,869
`9,765,379
`10,017,732
`10,112,994
`10,421,984
`10,829,732
`8,383,773
`9,688,775
`7,070,959
`9,222,106
`9,254,338
`9,669,069
`9,816,110
`10,130,681
`D858,754
`10,406,226
`10,415,055
`10,464,992
`10,669,594
`10,828,345
`10,857,205
`10,857,231
`D906,102
`10,888,601
`10,905,786
`10,918,754
`10,927,342
`10,973,879
`11,053,280
`
`Patent Expiration Date
`2035-07-31T00:00:00.000Z
`2032-09-17T00:00:00.000Z
`2031-05-26T00:00:00.000Z
`2034-03-14T00:00:00.000Z
`2031-08-18T00:00:00.000Z
`2034-03-14T00:00:00.000Z
`2033-10-12T00:00:00.000Z
`2030-08-06
`2028-07-08
`2021-11-01T00:00:00.000Z
`2022-07-08T00:00:00.000Z
`2023-10-17T00:00:00.000Z
`2028-07-08T00:00:00.000Z
`2034-03-10T00:00:00.000Z
`2034-03-14T00:00:00.000Z
`2035-11-05T00:00:00.000Z
`2033-09-19T00:00:00.000Z
`2034-03-14T00:00:00.000Z
`12/13/23
`12/31/22
`June 16, 2023
`June 4, 2028
`May 22, 2032
`January 11, 2032
`October 21, 2035
`January 11, 2032
`September 3, 2034
`March 22, 2026
`June 4, 2028
`June 14, 2027
`February 12, 2037
`January 11, 2032
`January 11, 2032
`Disclaimer filed on March 14, 2022
`December 29, 2035
`January 11, 2032
`March 6, 2038
`March 6, 2038
`August 3, 2036
`May 17, 2039
`August 18, 2040
`
`https://purplebooksearch.fda.gov/patent-list
`
`Mylan Exhibit 1166
`Mylan v. Regeneron, IPR2021-00881
`Page 3
`
`
`
`BLA Number
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`125387
`
`Applicant Name
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`Regeneron Pharmaceuticals, Inc.
`
`Proprietary Name
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`Eylea
`
`Proper Name
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`aflibercept
`
`Patent Number
`11,066,458
`11,084,865
`11,104,715
`D934,069
`11,160,918
`11,174,283
`11,186,625
`11,253,572
`
`Patent Expiration Date
`June 14, 2027
`June 14, 2027
`August 18, 2040
`October 26, 2036
`July 29, 2039
`August 18, 2040
`August 18, 2040
`January 11, 2032
`
`https://purplebooksearch.fda.gov/patent-list
`
`Mylan Exhibit 1166
`Mylan v. Regeneron, IPR2021-00881
`Page 4
`
`